DURECT Corp - Company Profile
Powered by
All the data and insights you need on DURECT Corp in one report.
- Save hours of research time and resources with
our up-to-date DURECT Corp Strategy Report
- Understand DURECT Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
DURECT Corp (Durect) is a biopharmaceutical company that focuses on the research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. Durect also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.
DURECT Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Osmotic Pump | Posidur |
Biodegradable Polymer | Saber |
Pipeline | Cloud |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
Competitor Comparison
Key Parameters | DURECT Corp | AbbVie Inc | AstraZeneca Plc | Eli Lilly and Co | Medtronic Plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United Kingdom | United States of America | Ireland |
City | Cupertino | North Chicago | Cambridge | Indianapolis | Dublin |
State/Province | California | Illinois | England | Indiana | - |
No. of Employees | 72 | 50,000 | 89,900 | 43,000 | 95,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gail Maderis | Chairman | Executive Board | 2023 | - |
James E. Brown, D.V.M. | Director; Chief Executive Officer; President | Executive Board | 1998 | 66 |
Timothy M. Papp, M.B.A. | Chief Financial Officer | Senior Management | 2022 | 47 |
Norman L. Sussman, M.D., FAASLD | Chief Medical Officer | Senior Management | 2020 | 69 |
Andrew R. Miksztal Ph.D | Vice President - Pharmaceutical Research and Development; Principal Scientist | Senior Management | 2000 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward